Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alcon, Allergan argue FDA pre-emption in defense against class-action suits.

This article was originally published in The Tan Sheet

Executive Summary

ALCON, ALLERGAN PRE-EMPTION DEFENSE IN CONTACT LENS SOLUTION LAWSUITS will be argued in hearings set for June 7 in the case of Nicholas v. Alcon and June 14 in Bruno v. Allergan. The two manufacturers will assert at the hearings in California Superior Court in San Diego that federal device law pre-empts the plaintiffs' claims of false advertising and unfair business practices.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts